Quick filters
- European equity funds ride recent market rally Globe and Mail | Sunday May 19, 2013 7:00PM
- Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis PR Newswire | Friday May 17, 2013 8:00AM
- Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month PR Newswire | Thursday May 16, 2013 8:00AM
- Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA) PR Newswire | Wednesday May 15, 2013 1:00AM
- New Gold Bond® No Mess Powder Spray Introduced by Sanofi's Chattem PR Newswire | Monday May 6, 2013 3:13PM
- Sanofi: Q1 2013 business EPS(1) impacted by exclusivity losses in prior year PR Newswire | Thursday May 2, 2013 7:00AM
- Sanofi Q1 2013 - Interview with CFO Jérôme Contamine Business Wire | Thursday May 2, 2013 1:45AM
- Danish drug makers recuperating nicely Globe and Mail | Wednesday May 1, 2013 11:41AM
- Sanofi Pasteur Scholarships awarded to four HEC Montréal students CNW Group | Wednesday May 1, 2013 9:00AM
- NextBio Announces Translational Medicine Partnership with Sanofi PR Newswire | Tuesday April 30, 2013 8:00AM
- Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study Business Wire | Thursday April 25, 2013 1:00AM
- Glaxo loses thirst for iconic beverage brands Globe and Mail | Wednesday April 24, 2013 2:51PM
- Genzyme Convenes 13th European Fabry Disease Roundtable Business Wire | Thursday April 18, 2013 8:00AM
- Genzyme's Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis Business Wire | Monday April 8, 2013 9:00AM
- Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments Business Wire | Monday March 25, 2013 2:00AM
- Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis Business Wire | Friday March 22, 2013 8:30AM
- AstraZeneca outlook long on hope, short on details Globe and Mail | Thursday March 21, 2013 3:36PM
- Effect of Genzyme's LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies Business Wire | Thursday March 21, 2013 3:00PM
- Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness PR Newswire | Thursday March 14, 2013 8:30AM
- Genzyme's Multiple Sclerosis Franchise Featured at AAN Business Wire | Wednesday March 13, 2013 2:00AM
Live Discussion of SNY on StockTwits